Stratified medicine paediatrics: genomic characterisation of relapsed paediatric cancers for diagnostics and stratified therapy

Institute of Cancer Research, London0 sites550 target enrollmentJanuary 28, 2019

Overview

No summary available.

Registry

who.int

Start Date

January 28, 2019

End Date

April 30, 2027

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Institute of Cancer Research, London

•Current inclusion criteria as of 15/03/2023:
•1\. Patients with a relapsed or refractory paediatric tumour (all solid tumours, central nervous system (CNS) tumours and lymphoma) or leukaemia
•2\. For solid tumours: Formalin fixed paraffin embedded (FFPE) tumour available from a biopsy, resection or other surgical procedure that was taken within 8 weeks of trial entry\*
•3\. For leukaemia: Viable fresh or frozen Bone Marrow aspirate sample taken at a prior assessment within 8 weeks prior to trial entry\*\*
•3\. Written informed consent of patient/parent/guardian/legal guardian\*\*\*
•\* To allow full multi\-omic analysis both fresh frozen and Formalin fixed paraffin embedded (FFPE) tumour plus a blood sample for constitutional (germline) and circulating tumour (ct) DNA will need to be available.
•Original diagnostic slides should be submitted at the same time as block from current relapse/refractory episode either in same shipment.
•\*\* Where available, a cerebrospinal fluid (CSF) sample in the event of an isolated or combined CNS relapse should also be provided in addition to the bone marrow aspirate.
•\*\*\* Some adult patients with brain tumours or brain metastases may be incapable of providing their own consent due to the neurological effects of their disease. In such cases, these patients will be classed as an incapacitated adult and a consultee will be sought.
•Previous inclusion criteria: